



**FOR IMMEDIATE RELEASE**

## **Affimed to Present at the 2017 Wells Fargo Healthcare Conference – Boston**

*Heidelberg, Germany, September 4, 2017* - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Adi Hoess, CEO, will present at the 2017 Wells Fargo Healthcare Conference on Thursday, September 7, 2017 at 9:25 a.m. (ET) in Boston.

A live webcast of the conference presentation can be accessed through the “Events” section on the “Investors & Media” page of the Affimed website at <http://www.affimed.com/events.php>. A replay of the presentation will be available from Affimed’s website for 30 days following the conference.

### **About Affimed N.V.**

Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit [www.affimed.com](http://www.affimed.com).

### **IR Contact:**

Caroline Stewart, Head IR  
Phone: +1 347 394 6793  
E-Mail: [IR@affimed.com](mailto:IR@affimed.com) or [c.stewart@affimed.com](mailto:c.stewart@affimed.com)

### **Media Contact:**

Anca Alexandru, Head of Communications, EU IR  
Phone: +49 6221 64793341  
E-Mail: [a.alexandru@affimed.com](mailto:a.alexandru@affimed.com)